Search
Tea tree oil
go.drugbank.com/drugs/DB11218ApprovedNutraceuticalThe dermatological use of tea tree oil has been investigated by various studies, where several studies have suggested the uses of this oil for the treatment of acne vulgaris, seborrheic dermatitis, and … It may be referred to as _Melaleuca alternifolia_ oil.
Mixtures: I Dew Care Tea Tree O StarterkitSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational[L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … [A257330] In February 2023, the use of sparsentan to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression was approved by the FDA under
Categories: Agents Acting on the Renin-Angiotensin SystemHepatitis B Vaccine (Recombinant)
go.drugbank.com/drugs/DB11627ApprovedInvestigationalWithdrawnThere is no specific treatment for hepatitis. … Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen.
Temozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigational[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow … It is currently marketed under the trademark TEMODAR® by Merck.[L32033]
Samarium (153Sm) lexidronam
go.drugbank.com/drugs/DB05273ApprovedSamarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. … Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help
Categories: Analgesics, Non-NarcoticAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient.
AstraZeneca COVID-19 Vaccine
go.drugbank.com/drugs/DB15656ApprovedInvestigationalclots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis. … Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood
Cidofovir
go.drugbank.com/drugs/DB00369ApprovedInvestigational[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Thioproperazine
go.drugbank.com/drugs/DB01622ApprovedIt is virtually without antiserotonin and hypotensive action and has no antihistaminic property. … It is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Synonyms: N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine-2-sulfonamide, N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine-2-sulfonamide